

Defining and grading an obstructive ventilatory defect (OVD): 'FEV₁/FVC lower limit of normal (LLN) vs. Z-score' and 'FEV₁ percentage predicted (%pred) vs. Z-score'

Rim Kammoun, Ines Ghannouchi, Sonia Rouatbi & Helmi Ben Saad

To cite this article: Rim Kammoun, Ines Ghannouchi, Sonia Rouatbi & Helmi Ben Saad (2018) Defining and grading an obstructive ventilatory defect (OVD): 'FEV₁/FVC lower limit of normal (LLN) vs. Z-score' and 'FEV₁ percentage predicted (%pred) vs. Z-score', *Libyan Journal of Medicine*, 13:1, 1487751, DOI: [10.1080/19932820.2018.1487751](https://doi.org/10.1080/19932820.2018.1487751)

To link to this article: <https://doi.org/10.1080/19932820.2018.1487751>



© 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



Published online: 21 Jun 2018.



Submit your article to this journal [↗](#)



Article views: 68



View Crossmark data [↗](#)

Defining and grading an obstructive ventilatory defect (OVD): 'FEV₁/FVC lower limit of normal (LLN) vs. Z-score' and 'FEV₁ percentage predicted (% pred) vs. Z-score'

Rim Kammoun^a, Ines Ghannouchi^{a,b}, Sonia Rouatbi^{a,c} and Helmi Ben Saad^{a,d}

^aDepartment of Physiology and Functional Explorations, Farhat HACHED Hospital, Sousse, Tunisia; ^bLaboratory of Physiology, Faculty of Medicine of Sousse, University of Sousse, Sousse, Tunisia; ^cHeart Failure (LR12SP09) Research Laboratory, Farhat Hached Hospital, Sousse, Tunisia; ^dInternational Center of Functional Explorations, Sousse, Tunisia

ABSTRACT

An obstructive ventilatory defect (OVD) is defined by a low forced expiratory volume/forced/slow vital capacity (FEV₁/FVC) (e.g. <lower limit of normal (LLN)). However, the LLN can be estimated either by the 90% confidence interval (or the 90th percentile) (American Thoracic and the European Respiratory Societies (ATS/ERS) method) or by the Z-score (global lung initiative (GLI) method). In 2014, a new alternative classification (GLI classification) for grading the OVD severity was proposed to replace the 2005-ATS/ERS one. The aims of the present study were to determine, according to the two methods (GLI vs. ATS/ERS), the frequency of participants having an OVD; and to compare the two classifications (GLI vs. ATS/ERS) of OVD severity. This was a prospective study including 1000 participants (mean age = 41 ± 10 years). The OVD was defined according to the ATS/ERS [FEV₁/FVC < LLN (=local norms value - 1.64 × residual standard deviation)] and GLI (FEV₁/FVC Z-score < -1.64) criteria. The following OVD classifications severity were applied: ATS/ERS (FEV₁%pred): mild (>70%), moderate (60–69%), moderately severe (50–59%), severe (35–49%), and very severe (<35%) and GLI (FEV₁ Z-score): mild (≥ -2.0), moderate (-2.0 to -2.5), moderately severe (-2.5 to -3.0), severe (-3.0 to -4.0), and very severe (<-4.0). The frequencies of OVD were 14.4% (ATS/ERS method) and 10.5% (GLI method) ($p < 0.05$). Among the 103 participants having an OVD according to the two methods, the severity classification was mild (34.95% vs. 37.86%, $p < 0.05$), moderate (25.24% vs. 18.45%, $p < 0.05$), moderately severe (23.30% vs. 15.53%, $p = 0.144$), severe (9.71% vs. 20.39%, $p < 0.05$), and very severe (6.80% vs. 7.77%, $p = 0.785$), respectively for the ATS/ERS and GLI classifications. The two OVD definitions were not exchangeable. Moreover, the two grading severity systems misclassified the OVD grades.

ARTICLE HISTORY

Received 3 May 2018
Accepted 5 June 2018

KEYWORDS

Bronchial obstruction;
diagnosis; interpretation;
international guidelines

In adults with a prior evidence of lung disease, an obstructive ventilatory defect (OVD) is usually defined by a low ratio between the 1st forced expiratory volume and the 'forced/slow' vital capacity [FEV₁/(F)VC] (e.g. <lower limit of normal (LLN)) [1,2]. In practice, once the OVD diagnosis is retained, it is essential to grade its severity into five degrees based on the FEV₁ [1,3]. However, nowadays, there is no clear consensus, neither as to what constitutes a LLN, nor as to how express the FEV₁.

Two methods were recommended by the American Thoracic and the European Respiratory Societies (ATS/ERS) [1] and by the global lung initiative (GLI) [2], to estimate the LLN. According to the ATS/ERS [1], the LLN can be estimated either as the 90% confidence interval using Gaussian statistics (in case of normal distribution) or with a nonparametric technique, such as the 90th percentile (in case of skewed distribution) [1]. In practice, the 90% LLN of each spirometric data is obtained

by the subtraction of '1.64 × residual standard deviation (SD)' from the predicted value [1]. For example, the LLN of FEV₁ is equal to 'FEV₁ predicted value - 1.64 × residual SD'. While according to the ATS/ERS [1], the aforementioned SD is a fixed value whatever the age, for the GLI [2], it is a coefficient of variation that varies with age and, hence it must be modeled. According to the GLI, the LLN is considered as a Z-score lower than '-1.64' [2]. The Z-score is derived using the LMS method ['L' for lambda or location (index of skewness), 'M' for mu or mean value, and 'S' for sigma or scatter (coefficient of variation)] and using the generalized additive models for location, scale, and shape (GAMLSS) technique [4]. The principle of the LMS method is that the distribution of the outcome variable **Y** is defined by three age-varying parameters λ , μ , σ such that the transformed outcome: $Z = [(Y/\mu)^\lambda - 1]/(\lambda \times \sigma)$ [5]. The Z-score is the signed number of SDs by which the value of a

CONTACT Helmi Ben Saad  helmi.bensaad@rns.tn  Laboratory of Physiology, Faculty of Medicine of Sousse, Street Mohamed Karoui, Sousse 4000, Tunisia

© 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

measured spirometric data differs from the mean value of what is being predicted, with merely 5% of healthy subjects having a Z-score of 1.64 or less [2,6].

The severity of the OVD correlates with the ability to work and function in daily life, morbidity, respiratory complaints, and prognosis, including a fatal outcome [7]. Surprisingly, there is a disagreement between the ATS/ERS and the GLI on the way to express the FEV₁ [1,3]. While the ATS/ERS classification is based on the FEV₁ expressed in percentage of the predicted value (%pred) [1], the GLI new classification is based on the FEV₁ Z-scores [3]. This could be a source of confusion [6,8].

The present *Scientific Letter* aimed to ascertain how well the GLI criteria to diagnosis the OVD [2] and to grade its severity [3] fit those recommended by the ATS/ERS [1].

A cross-sectional study including 1000 participants (145 females) was performed in a private function exploration center (<http://placesmap.net/TN/centre-international-d-explorations-fonctionnelles-163323/>). Measurements were carried by a plethysmograph (Jaeger MasterScreen Body, CareFusion Germany). Local norms [9] were applied to derive the predicted values and the LLN. The Z-scores were derived for each participant using norms from the GLI basing specially on developed software [10]. The OVD was defined according to the ATS/ERS [FEV₁/FVC < LLN (=local norms value – 1.64 × residual SD) [1]] and the GLI [FEV₁/FVC Z-score < ‘–1.64’ [2]] criteria. The following two severity classifications were applied: ATS/ERS [1] [based on the FEV₁%pred [11,12]: mild (>70%), moderate (60–69%), moderately severe (50–59%), severe (35–49%), and very severe (<35%); GLI [based on the FEV₁ Z-score [3]: mild (≥–2.0), moderate (–2.5 to –2.0), moderately severe (–3.0 to –2.5), severe (–4.0 to –3.0), and very severe (<–4.0)]. Analyses were carried out using Statistica software (Statistica Kernel version 6; StatSoft, Paris, France). Significance was set at the 0.05 level. Descriptive analysis includes frequencies for categorical variables and mean ± SD for continuous ones. Chi-square test was used to assess the agreement between the presence of OVD or its severity degree according to the two classifications (GLI vs. ATS/ERS). The relationships between the three spirometric data (FEV₁, FVC, and FEV₁/FVC) expressed as %pred and their Z-scores were evaluated using the correlation coefficient (*r*).

The total sample age, height, and weight mean ± SD were, respectively, 41.29 ± 10.30 years, 1.71 ± 0.08 m, and 80.9 ± 12.2 kg. Twenty percent of participants were smokers or ex-smokers. The determined FEV₁ (L, %pred), FVC (L, %pred), and FEV₁/FVC (absolute value, %pred) were, respectively, 3.37 ± 0.79 (84 ± 14%), 4.25 ± 0.89 (90 ± 12%), and 0.79 ± 0.08 (97 ± 9%). According to the GLI norms, their

mean ± SD Z-scores were, respectively, –0.87 ± 1.04, –0.75 ± 0.93, and –0.26 ± 1.04. There were strong and significant linear relationships between data expressed as %pred and their Z-scores (*r* = 0.9280 for FEV₁, *r* = 0.9210 for FVC and *r* = 0.9689 for FEV₁/FVC). The frequencies of participants having an OVD were 14.4% and 10.5%, respectively with the ATS/ERS and the GLI methods (*p* < 0.05). Conformity of OVD diagnosis was found in 103 cases. Among the 144 participants having an OVD according to the ATS/ERS method, 41 were free from OVD according to the GLI method. Among the 105 participants having an OVD according to the GLI method, only two were free from OVD according to the ATS/ERS method. Moreover, the two grading severity systems misclassified the grades of OVD (Pearson Chi-square = 214.095, *df* = 16, *p* < 0.05). In fact, for the 103 participants having OVD according to the ATS/ERS and the GLI methods, the severity classification was mild (34.95% vs. 37.86%, *p* < 0.05), moderate (25.24% vs. 18.45%, *p* < 0.05), moderately severe (23.30% vs. 15.53%, *p* = 0.144), severe (9.71 vs. 20.39%, *p* < 0.05), and very severe (6.80% vs. 7.77%, *p* = 0.785).

The main result of this study was that the diagnosis and the classification of the OVD using the GLI method [2,3] resulted in a change in the frequencies and the severity degrees established by the ATS/ERS recommendations [1].

It is conventional that a diagnosis of an OVD should be based on an abnormally low FEV₁/(F)VC ratio [3]. Unexpectedly, there is no worldwide consensus on what constitutes a low FEV₁/(F)VC ratio [3,13]. Whereas the ATS/ERS [1] advocated use of the 5th percentile of FEV₁/(F)VC from a healthy population as the LLN, the GLI [2] adopted the Z-score value of FEV₁/FVC. According to the GLI [2], unlike %pred the Z-score is free from bias due to age, height, sex, and ethnic group. In this study, the two OVD definitions (GLI vs. ATS/ERS) were not exchangeable. The above result was contrary to that found in another larger study (*n* = 21,191 participants) [3], where the overall prevalence of OVD was identical with the ATS/ERS [1] and the GLI [3] definitions. The authors concluded that this allows reliable reconstruction of ATS/ERS criterion diagnosis by simple replacement of the LLN with Z-score [3]. This study findings do not support the above conclusion and confirmed previous result that adopting the GLI norms [2] will have significant effects on the proportions of detection of spirometric defects [11].

The GLI new classification system was described as effortless, simply remembered, and clinically convincing [3]. It seems that it retains formerly established links with clinical results and circumvents biases due to the use of FEV₁%pred [3]. According to Quanjer et al. [3], when merged with the GLI norms [2], it supplies a universal diagnostic

standard, gratis of bias due to age, height, sex, and ethnic group. Similar to this study, another one [3] found a robust linear relationship between FEV₁% pred and FEV₁ Z-score ($r = 0.99$). The authors [3] concluded that this permits unflinching rebuilding of ATS/ERS severity classification cut-off values by simple substitution of FEV₁%pred with Z-score. In addition, they found that using the LLN for FEV₁/(F)VC and Z-scores for FEV₁ of -2, -2.5, -3, and -4 to demarcate severity grades of OVD results in close arrangement with ATS/ERS severity classifications [3]. This study finding do not support the above conclusions. In the cohort study of Tejero et al. [8] ($n = 2614$ patients with chronic obstructive pulmonary disease (COPD)), based on ATS/ERS [1] and GLI [11] classifications, 33.2% and 35.7% had mild, 39.9% and 36.2% had moderate, 18.5% and 20.9% had severe, and 8.3% and 7.3% had very severe OVD. Like in this study, in the aforementioned one [8], the classification based on Z-score [3] showed little concordance with the ATS/ERS classification [1]: according to the Z-score classification [3], 66.3% of COPD remained with the same severity, while 23.7% worsened and 10.0% improved.

The low percentage of females (14.5%) included in this study, makes the 'generalization' of the findings questionable, and a little bit 'biased'. In order to avoid such biased assessment of outcomes and the sex-related effect on spirometric data [14,15], it was better to include similar percentages of both sexes. However, the observed low percentage of females was similar to that reported in a previous local study where females represented 19.6% of the total sample [11].

In conclusion, the rationale behind the remodeled scheme for diagnosing OVD and for classifying spirometric deficiency is interesting. It will afford the occasion for a universal standard for presentation and reading of spirometry. However, in some regions (e.g. North Africa), their application with the GLI norms should be taken with cautions. Again, the GLI group [2] is asked to consider North African population as an individual ethnic group and to create an adjustment factor for it. A larger number of North African participants with OVD or COPD will be needed to analyze the real application of the GLI [3] adjustment on diagnosing OVD and classifying its severity.

Acknowledgments

Authors wish to express their sincere gratitude to the following five Pulmonologists from Sousse, Tunisia: Halima Ben Salem, Mohamed Moez Ben Sayah, Mohamed Salah Tlili, Souhail Slama and Mohamed Ben Saad.

Authors' contributions

RK conceived the study, participated in its design, performed the statistical analysis, and helped to draft the manuscript.

IG conceived the study, participated in its design and helped to draft the manuscript.

SR conceived the study, participated in its design and helped to draft the manuscript

HBS conceived the study, participated in its design, performed the statistical analysis, helped to draft the manuscript and coordinated the study.

All authors read and approved the final manuscript.

Disclosure statement

HBS reports personal fees from AstraZeneca, Boehringer Ingelheim, INPHA-MEDIS and Chiesi. The remaining authors declare that they have no conflicts of interest concerning this article.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

ORCID

Sonia Rouatbi  <http://orcid.org/0000-0003-3411-1182>

Helmi Ben Saad  <http://orcid.org/0000-0002-7477-2965>

References

- [1] Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. *Eur Respir J.* 2005 Nov;26(5):948–968. PubMed PMID: 16264058; eng.
- [2] Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. *Eur Respir J.* 2012 Dec;40(6):1324–1343. PubMed PMID: 22743675; PubMed Central PMCID: PMC3786581. eng.
- [3] Quanjer PH, Pretto JJ, Brazzale DJ, et al. Grading the severity of airways obstruction: new wine in new bottles. *Eur Respir J.* 2014 Feb;43(2):505–512. PubMed PMID: 23988764; eng.
- [4] Cole TJ, Stanojevic S, Stocks J, et al. Age- and size-related reference ranges: a case study of spirometry through childhood and adulthood. *Stat Med.* 2009 Feb 28;28(5):880–898. PubMed PMID: 19065626; PubMed Central PMCID: PMC2798072. eng.
- [5] Rigby RA, Stasinopoulos DM. Generalized additive models for location, scale and shape (with discussion). *J Royal Statistical Society: Series C (Applied Statistics).* 2005;54(3):507–554.
- [6] Ben Salah N, Bejar D, Snène H, et al. The Z-score: a new tool in the interpretation of spirometric data. *Tunis Med.* 2017;95(8):767–771.
- [7] Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. *Eur Respir J.* 2005 Aug;26(2):319–338. PubMed PMID: 16055882; eng.
- [8] Tejero E, Prats E, Casitas R, et al. Classification of airflow limitation based on Z-score underestimates mortality in patients with chronic obstructive pulmonary disease.

- Am J Respir Crit Care Med. 2017 Aug 1;196(3):298–305. PubMed PMID: 28306326; eng.
- [9] Tabka Z, Hassayoune H, Guenard H, et al. Spirometric reference values in a Tunisian population. *Tunis Med.* 1995 Feb;73(2):125–131. PubMed PMID: 9506154.
- [10] GLI-2012 desktop software for individual calculations. <http://www.ers-education.org/guidelines/global-lung-function-initiative/spirometry-tools/desktop-individual-calculator.aspx>. Last access Jun 3rd 2018.
- [11] Ben Saad H, El Attar MN, Hadj Mabrouk K, et al. The recent multi-ethnic global lung initiative 2012 (GLI2012) reference values don't reflect contemporary adult's North African spirometry. *Respir Med.* 2013 Dec;107(12):2000–2008. PubMed PMID: 24231283; eng.
- [12] El Attar MN, Hadj Mabrouk K, Ben Abdelaziz A, et al. Applicability of the old European respiratory society/ European community for steel and coal reference equations for spirometry interpretation in Tunisian adult population. *Tunis Med.* 2014 Aug-Sep;92(8–9):574–580. PubMed PMID: 25815546; eng.
- [13] Affes Z, Rekik S, Saad HB. Defining obstructive ventilatory defect in 2015. *Libyan J Med.* 2015 Jan;10(1):28946. . PubMed PMID: 28349796; eng.
- [14] Suresh K. An overview of randomization techniques: an unbiased assessment of outcome in clinical research. *J Hum Reprod Sci.* 2011 Jan;4(1):8–11. . PubMed PMID: 21772732; PubMed Central PMCID: PMC3136079.
- [15] Liptzin DR, Landau LI, Taussig LM. Sex and the lung: observations, hypotheses, and future directions. *Pediatr Pulmonol.* 2015;50(12):1159–1169. Epub 2015/04/25.